Whitehaven Coal Limited (WHITF) Receives a Buy from Morgan Stanley
Confident Investing Starts Here:
Anand covers the Basic Materials sector, focusing on stocks such as Rio Tinto Limited, Evolution Mining , and Iluka Resources Limited. According to TipRanks, Anand has an average return of 5.8% and a 48.00% success rate on recommended stocks.
Currently, the analyst consensus on Whitehaven Coal Limited is a Moderate Buy with an average price target of $4.13, representing a 21.47% upside. In a report released on May 12, Morgans also maintained a Buy rating on the stock with a A$7.25 price target.
Based on Whitehaven Coal Limited's latest earnings release for the quarter ending December 31, the company reported a quarterly revenue of $3.43 billion and a net profit of $77 million. In comparison, last year the company earned a revenue of $1.59 billion and had a net profit of $257.62 million
Based on the recent corporate insider activity of 12 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of WHITF in relation to earlier this year.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Insider
28 minutes ago
- Business Insider
Jarden Reaffirms Their Hold Rating on Northern Star Resources Ltd (NESRF)
In a report released on July 25, Ben Lyons from Jarden maintained a Hold rating on Northern Star Resources Ltd, with a price target of A$15.10. The company's shares closed last Friday at $10.80. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. According to TipRanks, Lyons is a 4-star analyst with an average return of 9.3% and a 69.23% success rate. Lyons covers the Basic Materials sector, focusing on stocks such as Northern Star Resources Ltd, Mineral Resources Limited, and 29metals Ltd.. In addition to Jarden, Northern Star Resources Ltd also received a Hold from UBS's Levi Spry in a report issued on July 25. However, on the same day, Canaccord Genuity maintained a Buy rating on Northern Star Resources Ltd (Other OTC: NESRF). The company has a one-year high of $15.27 and a one-year low of $8.57. Currently, Northern Star Resources Ltd has an average volume of 11.06K.
Business Insider
an hour ago
- Business Insider
Hesai upgraded to Overweight from Equal Weight at Morgan Stanley
Morgan Stanley upgraded Hesai (HSAI) to Overweight from Equal Weight with a price target of $26, up from $23. The firm believes the company continues to win market share amid growing LiDAR adoption in China. In addition, more overseas projects could enhance Hesai's margins while robotaxis and smart home robotic appliances will serve as another revenue growth driver from 2026 onwards, the analyst tells investors in a research note. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Yahoo
an hour ago
- Yahoo
Morgan Stanley Maintains a Buy on Exelixis (EXEL) With a $48 PT
Exelixis, Inc. (NASDAQ:EXEL) is one of the most profitable biotech stocks to invest in now. On July 22, Morgan Stanley analyst Sean Laaman maintained a Buy rating on Exelixis, Inc. (NASDAQ:EXEL) and set a price target of $48.00. A team of scientists in lab coats surrounded by pharmaceuticals and medical equipment, researching a life-saving oncology-focused biotechnology. The analyst reasoned that Exelixis, Inc. (NASDAQ:EXEL) recently updated its 2025 revenue guidance, increasing it to a $2.25-2.35 billion range after the higher-than-expected sales of Cabo. He attributed this optimistic outlook to the persistent demand growth and new patient starts in first-line renal cell carcinoma (1L RCC). Laaman also stated that Exelixis, Inc. (NASDAQ:EXEL) reported that it may update its guidance further as the NET launch progresses and additional revenue opportunities become clearer. Exelixis, Inc. (NASDAQ:EXEL) discovers, develops, and commercializes new medicines for difficult-to-treat cancers. Its product portfolio includes cabometyx, cometriq, and cotellic. While we acknowledge the potential of EXEL as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now. Disclosure: None. This article is originally published at Insider Monkey. Sign in to access your portfolio
